Availability: In Stock

Product description

Nomigren - combined preparation, has anti-migraine, antispasmodic analgesic effect.

Ergotamine is an ergot alkaloid, is a partial agonist of serotonin receptors, indiscriminately blocks 5-HT1A-1D receptors. For ergotamine, alpha-adrenergic blocking activity is combined with a pronounced direct vasoconstrictor effect on the smooth musculature of peripheral and cerebral vessels. In this regard, against the background of the action of ergotamine, a tonic effect on periphyric and cerebral vesicles prevails, which is of therapeutic importance in the management of migraine attacks.

Propiphenazone has analgesic effect.

Caffeine accelerates the absorption of ergotamine and enhances its therapeutic effect. Also, caffeine has a tonic effect on the cerebral vessels.

Camilophin exerts an antispasmodic effect, eliminating the initial vasospasm in the prodromal phase of a migraine attack.

Mekloxamine has anticholinergic, antihistamine, moderately sedative and antiemetic effects.


After ingestion, ergotamine is absorbed to a small extent from the gastrointestinal tract.

Bioavailability is low due to intensive metabolism during "primary passage" through the liver.

The main metabolites are secreted through the intestines with bile.

About 4% is excreted by the kidneys with urine unchanged.

The excretion of ergotamine is biphasic. The half-life (T 1/2) in the final phase is -21h.

Caffeine is well absorbed in the intestine (including fat). T 1/2 is about 5 hours. About 10% is excreted by the kidneys in an unchanged form.

After ingestion, about 25% of propiphenazone is metabolized by "primary passage" through the liver, the volume of distribution is 0.4 l / kg, the maximum concentration in the blood plasma is reached within 30-40 minutes. The maximum effect - after 90 minutes, T 1/2 -o2,1-2,4 h, is excreted by the kidneys with urine.

T 1/2 of mecloxamine and kamilofin - 1,5 - 2 h, are excreted by the kidneys with urine.


Acute migraine attacks (including those accompanied by aura) and migraine-like headaches of vascular genesis.


  • Hypersensitivity to the components of the preparation.
  • Organic diseases of the cardiovascular system (including acute myocardial infarction, angina pectoris, severe atherosclerosis, paroxysmal tachycardia, frequent ventricular extrasystole, arterial hypertension).
  • Obliterating diseases of peripheral vessels.
  • Glaucoma.
  • Benign hyperplasia of prostatic adenoma with a delay of urine.
  • Thyrotoxicosis.
  • Hepatic and / or renal insufficiency.
  • Sepsis.
  • Pregnancy.
  • Lactation period.
  • The age is under 15 years.
  • Lactose intolerance, lactase deficiency or glucose-galactose malabsorption (the preparation contains lactose).


  • Sleep disturbances.
  • Anxiety disorders (agoraphobia, panic disorder).
  • Megacolon.
  • Elderly age.
  • Simultaneous reception of glucocorticosteroids.
  • Migraine, accompanied by focal neurological disorders.

Suggested Use:


Nomigren should be taken at the very beginning of the attack.

For the first dose, the recommended dose is 1-2 tablets inside, with water, if after 30 minutes, there is no improvement, one or two more pills should be taken.

The maximum daily dose is not more than 4 tablets, the maximum dose within a week is not more than 10 tablets.

The preparationis not recommended to be used for a long time: after 7 days of use in cases requiring longer treatment, take a break for 3-4 days.

Special instructions:

Do not use the preparationto prevent a migraine attack!

Patients taking Nomigren should periodically monitor the blood picture.

With a systematic use of ergotamine-containing preparations, the patient should be advised to strictly adhere to prescribed doses in order to avoid the development of ergotism: spasm of peripheral vessels - loss of sensation, paresthesia, tingling sensation in the extremities, pain in the lower extremities, cyanosis (especially fingers), marked decrease pulsations, as well as violations from the central nervous system - Vertigo, stupor, coma convulsions.

When symptoms such as numbness of the fingertips of the hands or feet, pain in the heart, acceleration or slowing of the heart, the preparation should be stopped immediately and consult a doctor.

Impact on the ability to drive vehicles and manage mechanisms

Nomigen can affect the psychophysical capabilities of the patient, especially when taking concomitantly with alcohol or preparations depressing the central nervous system. Do not drive vehicles and work with potentially dangerous mechanisms for 2-3 hours after taking Nomigren.


  • Comes in original packaging. Item is brand new and unopened.


  • Keep away from direct sunlight.
  • Keep locked and away from children.
  • Store in dry place at room temperature.
  • Do not exceed storage temperature higher than 25 C

Important notice- the outer box design may vary before prior notice!


There are no reviews for this product.

Write a review

Buyers Online

Онлайн курсы IT